pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Pramipexole Dihydrochloride
drug
save

pramipexole dihydrochloride

Marketedupdated 4mo ago
by Shasun USA Inc
Approved
community read0 votes

indications

investigational
Parkinson's Disease

all catalysts(0)

nothing on the calendar yet

Trials studying pramipexole dihydrochloride

  • phase1Bioequivalence Study of Pramipexole Dihydrochloride Extended-release Tablets in Healthy Chinese Subjectscompletedn=49
  • phase3Phase III Long-Term Extension Study With Dexpramipexoleterminatedn=509
  • phase3A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)terminatedn=654
  • phase3A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.terminatedn=1,061
  • phase3A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthmaactive not recruitingn=600
  • phase2A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPDactive not recruitingn=30

Patent cliff

source: FDA Orange Book
first barrier falls
Apr 26, 2028
~1.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (14)

  • Sep 8, 2029formulationUS 86795333.0y
  • Sep 8, 2029formulationUS 86795333.0y
  • Sep 8, 2029formulationUS 86795333.0y
  • Sep 8, 2029formulationUS 86795333.0y
  • Sep 8, 2029formulationUS 86795333.0y
  • Sep 8, 2029formulationUS 86795333.0y
  • Sep 8, 2029formulationUS 86795333.0y
  • Apr 26, 2028formulationUS 76957341.7y
  • Apr 26, 2028formulationUS 76957341.7y
  • Apr 26, 2028formulationUS 76957341.7y
  • Apr 26, 2028formulationUS 76957341.7y
  • Apr 26, 2028formulationUS 76957341.7y
  • Apr 26, 2028formulationUS 76957341.7y
  • Apr 26, 2028formulationUS 76957341.7y

News(0)

no news has mentioned this drug yet

brand
Pramipexole Dihydrochloride
generic
pramipexole dihydrochloride
indication
Parkinson's Disease
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 5m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?